GlassScriptPhysician profile
Elyse Mills
NPI 1417505413
$5,852.00
in general payments reported to CMS, 2019-2025
34 companies · $69.74 in 2025
The $69.74 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,857 · 2022: $2,490 · 2023: $1,130 · 2024: $304 · 2025: $69.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $975.32 | 2021-2024 | |
| Acadia Pharmaceuticals INC | $603.46 | 2021-2024 | Nuplazid |
| Neurocrine Biosciences, INC. | $555.58 | 2022-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $456.58 | 2021-2023 | |
| Biogen, INC. | $427.05 | 2021-2023 | Vumerity, Tysabri |
| Teva Pharmaceuticals USA, INC. | $356.60 | 2021-2023 | Austedo Xr, Austedo, Ajovy |
| Novartis Pharmaceuticals Corporation | $321.09 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $287.76 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $228.33 | 2021 | |
| Allergan, INC. | $194.44 | 2021-2022 | |
| Genzyme Corporation | $191.47 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $175.36 | 2021-2022 | |
| Pfizer INC. | $146.28 | 2021-2024 | |
| Amgen INC. | $140.56 | 2021-2024 | Repatha, Otezla |
| Avanir Pharmaceuticals, INC. | $139.47 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $87.50 | 2021-2022 | |
| Lilly USA, LLC | $75.82 | 2021-2023 | Emgality |
| Mdd US Operations, LLC | $65.40 | 2022-2023 | Apokyn, Xadago |
| Alexion Pharmaceuticals, INC. | $64.14 | 2021-2023 | Ultomiris |
| Sumitomo Pharma America, INC. | $56.09 | 2023-2024 | Aptiom |
| Otsuka America Pharmaceutical, INC. | $48.89 | 2023 | Nuedexta |
| Supernus Pharmaceuticals, INC. | $36.62 | 2022-2023 | Oxtellar Xr, Trokendi Xr |
| Inspire Medical Systems, INC. | $27.66 | 2023 | Inspire |
| Glaxosmithkline, LLC. | $25.32 | 2024 | Trelegy Ellipta |
| Merz Pharmaceuticals, LLC | $21.30 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.56 | 2025 | Trintellix |
| Eisai INC. | $19.60 | 2021 | |
| Neurelis, INC. | $18.78 | 2023 | Valtoco |
| Incyte Corporation | $18.40 | 2023 | Monjuvi |
| Astrazeneca Pharmaceuticals LP | $15.79 | 2024 | Breztri |
| Global Blood Therapeutics, INC. | $14.44 | 2022 | |
| Ge Healthcare | $12.33 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Csl Behring | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elyse Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.